Skip to main content

14-02-2020 | ASCO GU 2020 | Conference coverage | Video

Researcher comment: Additional data from the EV-103 trial

Jonathan Rosenberg provides an update on the EV-103 trial of combined enfortumab vedotin plus pembrolizumab for the first-line treatment of cisplatin-ineligible advanced urothelial carcinoma (3:40).

Read transcript

ASCO GU 2020 conference hub

Image Credits